Fig. 6
Inhibition of abnormal osteogenic differentiation in vivo. (A) Cell-selective targeting capacity of CH6-MF NPs in vivo. The effects were measured by using fluorescence micrographs of ankle sections. Colocalization of Cy5.5-labelled CH6-MF NPs (red) and OCN (green) was detected, and the nuclei were stained with DAPI (blue). (B) Three-dimensional micro-CT reconstruction of the spine and ankle. The results showed osteophyte formation in the spine and ankles, and the quantification of the total volume of osteophytes in ankles is shown in the right panel. (C) Haematoxylin-eosin (H&E) and Safranin-O staining (SO-FG) of ankle sections. The results showed cartilage damage and bone destruction of the ankle joint. (D) Micro-CT coronal and horizontal images of the proximal tibia. BALB/c or Zap70mut mice were treated with CH6-MF or CH6-MF-Si NPs, and three-dimensional reconstruction was used to analyse the trabecular bone. (E) BA/BV, BV/TV, trabecular thickness, trabecular number and trabecular spacing. The results were analysed in BALB/c or Zap70mut mice treated with CH6-MF or CH6-MF-Si NPs. (G) Haematoxylin-eosin (H&E) staining of the heart, liver spleen and kidney to show the safety of the nanoparticles. Data were analysed by one-way ANOVA. The outcomes are presented as the mean ± SD. ns = statistically nonsignificant, *P < 0.05, **P < 0.01, and ***P < 0.001. Scale bar = 100 μm